FDA gives a thumbs up to Entyvio


The FDA approves Takeda's Entyvio (vedolizumab) for the treatment of moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease in adult patients who have not responded to one or more standard therapies.

Vedolizumab is an integrin receptor antagonist. Integrin receptors are proteins expressed on the surface of certain cells and function as bridges for cell-to-cell interactions. The mAb works by blocking the migration of circulating inflammatory cells across blood vessels and into areas of inflammation in the GI tract.

Related tickers: (SHPG) (JNJ) (AZN) (BIIB) (ABBV)

From other sites
Comments (2)
  • Dr Joseph Haluska
    , contributor
    Comments (499) | Send Message
     
    This is a huge and important advancement for many desperate and long-suffering people who have few effective therapies for these conditions. I dearly hope this brings them relief from the scourge of inflammatory bowel disease, and thank the researchers who are true heroes.
    -
    long JNJ, AZN, ABBV. and will be long BIIB and SHPG as soon as I scrape up the cash.
    20 May 2014, 06:49 PM Reply Like
  • doghousecontributor
    , contributor
    Comments (3019) | Send Message
     
    I have IBS and I am an investor in ABBV. I will be buying some more now, since we got a dip today in the market. I have dealt with it (IBS) for years, and seem to have it under control. Not my choice to take drugs, of which I have tried many, but nice to know ABBV may have a better solution.
    20 May 2014, 07:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs